Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...

Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership ...

There are rumors of a foldable iPhone, but new designs aren't on most people's list of upgrade must-haves. Dashia is the ...

Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Q1 2026 Management View CEO Thane Wettig said the quarter’s focus remained on “consistent progress we have made across our portfolio,” highlighting “FG-3246, our potential first-in-class antibody drug ...

Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic ...

From Genryo’s Sidewinder technology to the Festival of Genomics & Biodata in the UK earlier this year – AI might be trending, ...

A small model with a visual feedback loopAt the core of the system is Bioinspired3D, a 3-billion-parameter language model fine-tuned on a curated ...

SAN CARLOS, CA / ACCESS Newswire / May 11, 2026 / Form Bio, a leader in AI-powered genetic medicine development and genome engineering, today announced the launch of FormManufacturing™, a new platform ...

LanzaTech has partnered with the Technical University of Denmark’s Bright hub to set up a biofoundry to recycle emissions ...

CAMBRIDGE, Mass. - April 29, 2026. Researchers at the Massachusetts Institute of Technology have introduced Bioinspired123D, ...